연구동향 분석

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned

이대호 Vichien Srimuninnimit Rebecca Cheng Xin Wang Mauro Orlando 2015년

논문상세정보
인용/피인용
' Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • biological markers
  • epidermalgrowthfactorreceptor
  • non-small-cell lung carcinoma
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,315 1

0.0%

' Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned' 의 참고문헌

  • Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with nonsquamous non-small cell lung cancer
    Lee DH Eur J Cancer 49 : 3111 ~ 3121 [2013]
  • Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with nonsquamous non-small cell lung cancer
    Lee DH Eur J Cancer 49 3111-3121 [2013]
  • Target therapy in NSCLC patients : relevant clinical agents and tumour molecular characterisation
    Ulivi P Mol Clin Oncol 1 : 575 ~ 581 [2013]
  • Target therapy in NSCLC patients : relevant clinical agents and tumour molecular characterisation
    Ulivi P Mol Clin Oncol 1 575-581 [2013]
  • Symptom control and quality of life in LUX-Lung 3 : a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
    Yang JC J Clin Oncol 31 : 3342 ~ 3350 [2013]
  • Symptom control and quality of life in LUX-Lung 3 : a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
    Yang JC J Clin Oncol 31 3342-3350 [2013]
  • Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
    Ahn MJ Lung Cancer 77 : 346 ~ 352 [2012]
  • Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
    Ahn MJ Lung Cancer 77 346-352 [2012]
  • Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
    이대호 Cancer Research and Treatment 47 (4) : 616 ~ 629 [2015]
  • Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
    이대호 Cancer Research and Treatment 47 4 616-629 [2015]
  • Non-small cell lung carcinoma biomarker testing : the pathologist's perspective
    Brega E Front Oncol 4 : 182 ~ [2014]
  • Non-small cell lung carcinoma biomarker testing : the pathologist's perspective
    Brega E Front Oncol 4 182- [2014]
  • Non-small cell lung cancer : epidemiology, risk factors, treatment, and survivorship
    Molina JR Mayo Clin Proc 83 : 584 ~ 594 [2008]
  • Non-small cell lung cancer : epidemiology, risk factors, treatment, and survivorship
    Molina JR Mayo Clin Proc 83 584-594 [2008]
  • Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors : guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Lindeman NI Arch Pathol Lab Med 137 : 828 ~ 860 [2013]
  • Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors : guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Lindeman NI Arch Pathol Lab Med 137 828-860 [2013]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 : 121 ~ 128 [2010]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 121-128 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 : 2380 ~ 2388 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 2380-2388 [2010]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 : 947 ~ 957 [2009]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 947-957 [2009]
  • First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer : a randomised, phase 3 trial
    Yang JC Eur J Cancer 50 : 2219 ~ 2230 [2014]
  • First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer : a randomised, phase 3 trial
    Yang JC Eur J Cancer 50 2219-2230 [2014]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 : 239 ~ 246 [2012]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 239-246 [2012]
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study
    Zhou C Lancet Oncol 12 : 735 ~ 742 [2011]
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study
    Zhou C Lancet Oncol 12 735-742 [2011]
  • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Miller VA J Clin Oncol 22 : 1103 ~ 1109 [2004]
  • Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Miller VA J Clin Oncol 22 1103-1109 [2004]
  • Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors : a systematic review and meta-analysis
    Garassino MC Anticancer Res 29 : 2691 ~ 2701 [2009]
  • Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors : a systematic review and meta-analysis
    Garassino MC Anticancer Res 29 2691-2701 [2009]
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib
    Lynch TJ N Engl J Med 350 : 2129 ~ 2139 [2004]
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib
    Lynch TJ N Engl J Med 350 2129-2139 [2004]
  • A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology(PIONEER)
    Shi Y J Thorac Oncol 9 : 154 ~ 162 [2014]
  • A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology(PIONEER)
    Shi Y J Thorac Oncol 9 154-162 [2014]